{"entity":{"id":"imc-001","kind":"drug","name":"IMC-001","aka":["STI-3031"],"tldr":"IMC-001 is an experimental monoclonal antibody from ImmuneOncia Therapeutics, in phase 2 trials for extranodal NK/T-cell lymphoma, nasal type, TMB-high solid tumours and resectable gastric, oesophageal and liver cancer.","summary":"IMC-001 (STI-3031) is a monoclonal antibody (fully human IgG1) from ImmuneOncia Therapeutics, with Sorrento Therapeutics as registered STI-3031 (other name IMC-001) trials. A fully human IgG1 antibody against PD-L1 that blocks PD-1/PD-L1 binding and also triggers antibody-dependent cellular cytotoxicity by NK cells. Its furthest stage is phase 2, for extranodal NK/T-cell lymphoma, nasal type, TMB-high solid tumours and resectable gastric, oesophageal and liver cancer (investigator neoadjuvant study). ClinicalTrials.gov registers it in 5 studies linked below. Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"ImmuneOncia Therapeutics: immuneoncia.com","url":"https://www.immuneoncia.com/en/m24.php"},{"label":"ImmuneOncia Therapeutics: immuneoncia.com","url":"https://www.immuneoncia.com/en/m23.php"},{"label":"ImmuneOncia Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT04414163"},{"label":"ClinicalTrials.gov: trials of IMC-001","url":"https://clinicaltrials.gov/search?intr=IMC-001"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["extranodal-nk-t-cell-lymphoma","metastatic-cancer","hcc"],"sections":[],"technologies":[],"targets":["pdl1"],"drugs":[],"companies":["immuneoncia-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct04414163","nct06365840","nct03644056","nct04196465","nct05393713"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"IMC-001","modality":"Monoclonal antibody (fully human IgG1)","mechanism":"A fully human IgG1 antibody against PD-L1 that blocks PD-1/PD-L1 binding and also triggers antibody-dependent cellular cytotoxicity by NK cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/imc-001/","neighbours":{"cancer":[{"id":"extranodal-nk-t-cell-lymphoma","kind":"cancer","name":"Extranodal NK/T-cell lymphoma","route":"/cancers/extranodal-nk-t-cell-lymphoma/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"company":[{"id":"immuneoncia-therapeutics","kind":"company","name":"ImmuneOncia Therapeutics","route":"/companies/immuneoncia-therapeutics/"}],"trial":[{"id":"nct06365840","kind":"trial","name":"A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor","route":"/trials/nct06365840/"},{"id":"nct04414163","kind":"trial","name":"A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type","route":"/trials/nct04414163/"},{"id":"nct03644056","kind":"trial","name":"Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors","route":"/trials/nct03644056/"},{"id":"nct05393713","kind":"trial","name":"Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study","route":"/trials/nct05393713/"},{"id":"nct04196465","kind":"trial","name":"Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers","route":"/trials/nct04196465/"}]}}